bf/NASDAQ:MBRX_icon.jpeg

NASDAQ:MBRX

Moleculin Biotech, Inc.

  • Stock

1.01

−4.72%

0.36

USD last updated 14/08 01:46:41

Last Close

0.65

14/08 22:25

Market Cap

7.84M

Beta: 2.00

Volume Today

106.76K

Avg: 244.71K

PE Ratio

−0.62

PFCF: −0.65

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/tr...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -5-4-3-2-12017-05-152019-05-132021-05-122023-05-112024-08-13

    Revenue (Estimate*)

    50K100K150K200K2017-05-152019-05-132021-05-122023-05-112024-08-13

    *Estimate based on analyst consensus